低强度冲击波治疗糖尿病肾病:一项前瞻性1期研究
该前瞻性单臂1期研究纳入14例糖尿病合并3期慢性肾脏病患者,接受3周内6次低强度冲击波治疗,随访6个月。治疗总体耐受良好,未见对GFR和白蛋白尿的负面影响,白蛋白尿有下降趋势但无统计学差异。结论认为低强度冲击波治疗对糖尿病肾病是安全的,需更多患者以确定能否改善肾脏功能结局。
要点
- 低强度冲击波治疗在糖尿病肾病3期患者中总体耐受良好。
- 治疗未对GFR和白蛋白尿产生负面影响。
- 白蛋白尿6个月时有下降趋势但无统计学差异。
核心结论
- 低强度冲击波治疗对糖尿病肾病是安全的治疗方法。
- 需纳入更多患者以确定其能否改善肾脏功能结局。
研究设计与样本
- 前瞻性单臂1期研究,共纳入14例糖尿病合并3期慢性肾脏病患者。
- 患者接受3周内6次低强度冲击波治疗,每次每肾3000次冲击波,能量0.265 mJ/mm2,扩展焦距,频率4 Hz。
- 随访 visits 在1、3和6个月进行。
主要发现
- 治疗总体耐受良好,3例患者在治疗后立即出现短暂肉眼血尿。
- 多数患者治疗后出现持续至多2天的下背部压痛,无需镇痛治疗。
- 基线中位GFR为33.5 mL/min/1.73 m2(27.8-43.8),6个月随访时为36.0 mL/min/1.73 m2(27.5-52.0)。
- 基线中位白蛋白尿为256 mg/24 h(79-619),6个月后趋向下降至137 mg/24 h(41-404)。
- 基线与随访结果之间无统计学差异。
临床怎么用
- 低强度冲击波治疗可作为糖尿病肾病患者的一种安全治疗选择。
- 目前证据尚不足以推荐其用于改善肾脏功能结局,需更多研究验证。
局限性
- 样本量小(14例),为单臂1期研究。
- 随访时间较短(6个月)。
- 缺乏对照组,无法确定疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-intensity shockwave therapy (LI-SWT) is suggested as a therapy for promoting tissue regeneration. In pigs, it was recently found that LI-SWT improved renal function after ischaemic injury. Our objectives were to study glomerular filtration rate (GFR) and albuminuria in diabetic nephropathy (DN) after treatment with LI-SWT. The present pilot study reports on the clinical safety of LI-SWT in DN. METHODS: A total of 14 patients with diabetes mellitus and Stage 3 chronic kidney disease were recruited for this prospective, one-arm Phase 1 study. The patients were treated with six sessions of LI-SWT during a 3-week period. At each session, 3000 shockwaves were applied to each kidney with 0.265 mJ/mm2, extended focal size and 4 Hz. Follow-up visits were performed at 1, 3 and 6 months. RESULTS: In general, the treatment was well tolerated. Transient macroscopic haematuria was observed in three patients immediately after LI-SWT. The majority of patients experienced lower back tenderness lasting up to 2 days after treatment. There was no need for analgesic treatment. LI-SWT showed no negative effect on GFR and albuminuria. At baseline, median (interquartile range) GFR was 33.5 mL/min/1.73 m2 (27.8-43.8) compared with 36.0 mL/min/1.73 m2 (27.5-52.0) at 6 months follow-up. In parallel, median albuminuria was 256 mg/24 h (79-619) at baseline and tended to decrease to 137 mg/24 h (41-404) 6 months after LI-SWT. There was no statistical difference between baseline and follow-up results. CONCLUSIONS: LI-SWT is a safe treatment for DN. Inclusion of more patients is needed to determine whether LI-SWT can improve renal functional outcomes.
引用
- Skov-Jeppesen SM, Yderstraede KB, Bistrup C, et al. Low-intensity shockwave therapy in the treatment of diabetic nephropathy: a prospective Phase 1 study. Nephrol Dial Transplant. 2020. PMID: 30590575. doi:10.1093/ndt/gfy375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。